NeOnc Technologies Signs MoU with Abu Dhabi Health Dept

Calabasas, California and Abu Dhabi, United Arab Emirates - NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI), a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system cancers, has signed a Memorandum of Understanding (MoU) with the Department of Health - Abu Dhabi (DoH). The agreement aims to advance research and clinical capabilities in oncology and central nervous system therapeutics within the Emirate.

The proposed collaboration covers scientific and clinical exchange, specialist training, real-world evidence generation, and the assessment of clinical trial opportunities. Additionally, the partnership will explore a potential regional presence and manufacturing or distribution activities for NeOnc in Abu Dhabi.

Key Highlights

• Signing of an MoU between NeOnc and the Department of Health - Abu Dhabi during the Abu Dhabi Future Health Summit 2026.
• Focus on scientific exchange, specialist training, and clinical development methodologies for brain cancer and CNS tumors.
• Ongoing Compassionate Care program treating children in Abu Dhabi with investigational NEO100.
• Plans to work towards opening a Phase 1 study of NEO100 in the Emirate following prior Investigational New Drug status grants.